BOSTON (AP) — BOSTON (AP) — Monte Rosa Therapeutics Inc. (GLUE) on Tuesday reported a loss of $46.1 million in its fourth quarter.
The Boston-based company said it had a loss of 55 cents per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share.
The biopharmaceutical company posted revenue of $2.8 million in the period, also falling short of Street forecasts. Three analysts surveyed by Zacks expected $10.3 million.
For the year, the company reported a loss of $38.6 million, or 46 cents per share. Revenue was reported as $123.7 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on GLUE at https://www.zacks.com/ap/GLUE
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)
/Goldman%20Sachs%20Group%2C%20Inc_%20logo%20sign-by%20Poetra_RH%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/3D%20Graphics%20Concept%20Big%20Data%20Center%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/Meta%20Platforms%20by%20Primakov%20via%20Shutterstock.jpg)